AEArnold von Eckardstein

Arnold von Eckardstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arnold von Eckardstein has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A common functional variant on the pro-inflammatory Interleukin-6 gene may modify the association between long-term PM10 exposure and diabetes

    by Ikenna C. Eze, Medea Imboden, Ashish Kumar, Martin Adam, Arnold von Eckardstein, Daiana Stolz, Margaret W. Gerbase, Nino Künzli, Alexander Turk, Christian Schindler, et al.

    Air pollutants have been linked to type 2 diabetes (T2D), hypothesized to act through inflammatory pathways and may induce interleukin-6 gene (IL6) in the airway epithelium. The cytokine interleukin-6 may impact on glucose homeostasis. Recent meta-analyses showed the common polymorphisms, IL6 -572G > C and IL6 -174G > C to be associated with T2D risk. These IL6 variants also influence circulatory interleukin-6 levels. We hypothesize that these common functional variants may modify the association between air pollutants and T2D. We cross-sectionally studied 4410 first follow-up participants of the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases (SAPALDIA), aged 29 to 73 years who had complete data on genotypes, diabetes status and covariates. We defined diabetes as self-reported physician-diagnosed, or use of diabetes medication or non-fasting glucose >11.1 mmol/L or HbA1c > 0.065. Air pollution exposure was 10-year mean particulate matter C and IL6 -174G > C were 7 and 39 %. Mean exposure to PM10 was 22 μg/m3. Both variants were not associated with diabetes in our study. We observed a significant positive association between PM10 and diabetes among homozygous carriers of the pro-inflammatory major G-allele of IL6 -572G > C [Odds ratio: 1.53; 95 % confidence interval (1.22, 1.92); P interaction (additive) = 0.003 and P interaction (recessive) = 0.006]. Carriers of the major G-allele of IL6 -174G > C also had significantly increased odds of diabetes, but interactions were statistically non-significant. Our results on the interaction of PM10 with functionally well described polymorphisms in an important pro-inflammatory candidate gene are consistent with the hypothesis that air pollutants impact on T2D through inflammatory pathways. Our findings, if confirmed, are of high public health relevance considering the ubiquity of the major G allele, which puts a substantial proportion of the population at risk for the development of diabetes as a result of long-term exposure to air pollution.


  • Open Access

    Is there a need for novel cardiovascular risk factors?

    by Arnold von Eckardstein

    Atherosclerosis is a multifactorial disease whose age of onset and progression are strongly influenced by inborn and acquired risk factors. Since the pioneering work of the Framingham study, many prospective population and clinical studies have identified a series of independent risk factors for myocardial infarction, stroke and peripheral vascular disease, among which the pre-existence of atherosclerotic vascular disease, age, male gender, a positive family history of premature atherosclerotic disease, smoking, diabetes mellitus, hypertension, hypercholesterolaemia, hypertriglyceridaemia and low HDL cholesterol are considered as classical risk factors. Moreover, several large randomized and prospective intervention studies have demonstrated that smoking cessation as well as anti-hypertensive and lipid-lowering drug therapies help to reduce cardiovascular morbidity and mortality by ∼30% in both secondary and primary prevention. Despite these advances, we currently witness a controversy concerning the introduction of novel risk factors into clinical practice, specifically lipoprotein(a) [Lp(a)], C-reactive protein (CRP), fibrinogen, homocysteine and microalbuminuria.


  • Testosterone and atherosclerosis

    by Arnold von Eckardstein, Fredrick C.W Wu


  • Die Erkennung des Hochrisikopatienten für den Herzinfarkt

    by von Eckardstein, H Schulte, G Assmann

    Des études interventionnelles contrôlées ont prouvé l'efficacité thérapeutique de divers médicaments antihypertenseurs et hypolipémiants pour la prévention d'événements coronariens. Les directives internationales pour la prévention des maladies coronariennes concordent bien entre elles en ce qui concerne la prévention secondaire et recommandent pour les patients avec une maladie coronarienne manifeste une diminution de la pression artérielle en dessous de 140/90 mmHg et de la fraction LDL du cholestérol au moins en dessous de 3.0 mmol/l (2,6 mmol/l). Les recommandations de prévention primaire se concentrent sur le traitement de patients asymptomatiques à haut risque avec un risque d'infarctus du myocarde de plus de 2% par année. Pour calculer ce risque, l'évaluation des facteurs de risque suivants est nécessaire: le sexe, l'âge, l'anamnèse familiale d'infarctus du myocarde précoce, le tabagisme, la présence de diabète, la pression artérielle, le taux de cholestérol total, la fraction LDL de cholestérol, les triglycérides. Ces données permettent de calculer le risque absolu d'infarctus du myocarde par année grâce à divers scores ou algorithmes qui ont été construits à partir des résultats épidémiologiques d'études observationnelles.

  • Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux

    by Arnold Von Eckardstein, David Crook, Jolanda Elbers, Jennifer Ragoobir, Benjamin Ezeh, Frans Helmond, Norman Miller, Hans Dieplinger, Herjan Coelingh Bennink, Gerd Assmann

    Objective Androgens and other drugs that reduce plasma concentrations of high density lipoprotein (HDL) cholesterol are often considered to be pro‐atherogenic. Tibolone lowers HDL‐cholesterol by 20% ...


  • Low High-Density Lipoprotein Cholesterol

    by Martin Hersberger, Arnold von Eckardstein

    Low high-density lipoprotein (HDL) cholesterol is an important risk factor for coronary heart disease (CHD). In vitro, HDL exerts several potentially anti-atherogenic activities. HDLs mediate the reverse cholesterol transport (RCT) from peripheral cells to the liver, inhibit oxidation of low-density lipoprotein (LDL), adhesion of monocytes to the endothelium, apoptosis of vascular endothelial and smooth muscle cells and platelet activation, and stimulate the endothelial secretion of vasoactive substances as well as smooth muscle cell proliferation. Hence, raising HDL-cholesterol levels has become an interesting target for anti-atherosclerotic drug therapy. Levels of HDL cholesterol and the composition of HDL subclasses in plasma are regulated by apolipoproteins, lipolytic enzymes, lipid transfer proteins, receptors and cellular transporters. The interplay of these factors leads to RCT and determines the composition and, thereby, the anti-atherogenic properties of HDL. Several inborn errors of metabolism, as well as genetic animal models, are characterised by both elevated HDL cholesterol and increased rather than decreased cardiovascular risk. These findings suggest that the mechanism of HDL modification rather than simply increasing HDL cholesterol determine the efficacy of anti-atherosclerotic drug therapy. In several controlled and prospective intervention studies, patients with low HDL cholesterol and additional risk factors benefited from treatment with fibric acid derivatives (fibrates) or HMG-CoA reductase inhibitors (statins). However, only in some trials was prevention of coronary events in patients with low HDL cholesterol and hypertriglyceridaemia related to an increase in HDL cholesterol. We discuss the clinical and metabolic effects of fibrates, statins, nicotinic acid and sex steroids, and present novel therapeutic strategies that show promise in modifying HDL metabolism. In conclusion, HDL-cholesterol levels increase only moderately after treatment with currently available drugs and do not necessarily correlate with the functionality of HDL. Therefore, the anti-atherosclerotic therapy of high-risk cardiovascular patients should currently be focused on the correction of other risk factors present besides low HDL cholesterol. However, modification of HDL metabolism and improvement of RCT remain an attractive target for the development of new regimens of anti-atherogenic drug therapy.